东边不亮西边亮: 失败的心脏病药成了糖尿病试验药?

A Failed Heart Drug Becomes an Experimental Diabetes Drug
Posted by Jacob Goldstein
失败的心脏病药成了实验的糖尿病药
AtheroGenics’s stock has been on a tear (see the chart at left) since the company announced that new data on its “oral antidiabetic agent AGI-1067″ would be presented at a scientific meeting in Europe next week.
自从公司宣布，一个新的关于“口服抗糖药AGI-1067“的资料，将于下星期提交欧洲科学会上后。AtheroGenics’s股市下滑（见左侧列表）

Last we heard, AGI-1067 (also known as succinobucol) was a drug for patients who had been hospitalized because of a heart attack or unstable chest pain. But it failed to meet its primary goal in a study of those patients, and AstraZeneca, which had been working with AtheroGenics on the drug, abandoned the project.
据说，AGI-1067 (也就是 succinobucol)是一种，因心肌梗死或不稳定胸痛，住院病人服用的药。可是对这些病人的研究，其主要目的没有成功，与AtheroGenics合作的AstraZeneca放弃这一项目。

We did a little looking and realized we’d missed this announcement from a couple months back that said AGI-1067 had become a diabetes drug, based on a finding from the study of heart patients that the drug lowered blood sugar in patients with diabetes. And just last week, the company said it had started enrolling patients in a diabetes trial.
我们稍事了解，两个月前尚未获此公告，即，AGI-1067成了糖尿病药。根据一项心脏病人的研究，发现该药降低糖尿病人的血糖。只是上个星期，公司才宣称，已对糖尿病人进行试验

Diabetes is certainly a big market, but it’s worth keeping in mind that in the trial of heart patients (which will be the source of the data presented next week), one patient developed liver failure, which went away after the drug was stopped. And the drug also seemed to raise liver enzymes in some patients. For the Bernstein analyst cited in this Forbes article, that signal is reminiscent of the problems faced by Warner-Lambert’s Rezulin, pulled from the market in 2000, and AstraZeneca’s Exanta, which was never approved. (Pfizer was in the midst of acquiring Warner-Lambert when Rezulin was withdrawn.)
糖尿病无疑是一个大市场，不过在心脏病的试验中值得牢记（下周将发表资料来源），一个病人发生肝衰竭，停药后消失。在某些患者中，该药使肝酶升高。Forbes的文章Bernstein分析引证，Warner-Lambert’s Rezulin, 面对的回忆过去那些问题的信号，是从 2000年市场获得。AstraZeneca’s Exanta, 从未证实。（ 当Rezulin撤出时，Pfizer是在Warner-Lambert中间。

So it may take a lot of very strong data in diabetes patients to make regulators believe the drug’s benefits outweigh its possible risks to the liver.
因此糖尿病人要取得十分可靠的资料，使审核人员相信，药物的益处要超过可能发生的肝脏危险
编辑
一种由AtheroGenics合作AstraZeneca研究心肌梗死和胸痛的药物AGI-1067 (also known as succinobucol)，没有取得成功， AstraZeneca退出研究。在研究中，发现该药使糖尿病人的血糖降低
有资料提出，该药对肝脏有损害，因此糖尿病人必须取得十分可靠的资料，使审核人员相信，药物的益处要超过可能发生的肝脏危险